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he immune response tends to be regulated in
a dichotomous way. A consequence of this is
the observation that distinct immune effector
mechanisms can be activated in response to differ-
ent pathogens; these mechanisms are mainly sec-
ondary to the activation of B lymphocytes and of
humoral immunity, or to the activation ofcell-medi-
ated immunity. Activation of B lymphocytes, and
production of antibodies has been shown to be more
useful in defense against cell-free agents and toxins
(e.g., pneumococcus; tetanus toxins). In contrast,
triggering of cell-mediated immunity appears to be
effective against infections by cell-associated patho-
gens and parasites (e.g., leishmania; mycobacteria;
toxoplasma; treponema; HIV). 1’2
The mechanisms that regulate the induction of
humoral and cell mediated immunity have been clar-
ified by the identification in mice and man of two
functionally distinctT helper lymphocyte compart-
ments defined as T helper (TH1) and T helper 2
(TH2).
35 TH1 lymphocytes secrete interferon
gamma (IFNy) and interleukin (IL)-2 and mainly
promote cell mediated immunity;TH2 lymphocytes
secrete IL-4, and IL-5 and mainly stimulate the hu-
moral immunity and the generation of antibodies.3-5
Because cytokines are produced by cell types other
than T lymphocytes a functional definition was in-
troduced; thus, type i cytokines are defined as those
mainly stimulating cell mediated immunity whereas
type 2 cytokines mainly stimulate humoral immu-
nity. IL-2, IL-12, IFNy, and probably IL-15 are type
1 cytokines; IL-4, IL-5, IL-6, IL-10, and IL-13 are
type 2 cytokines. 6’7We will use this functional defini-
tion throughout the review.
Analyses of different pathologic and physiologic
conditions have revealed that selecting and activat-
ing the right weapon results in a better chance to
control and favourably influence these conditions.
In this review we will briefly summarize results
obtained when we examined humoral immunity
(HI) and cell mediated immunity (CMI) in condi-
tions as different as human immunodeficiency virus
(HIV) infection, neoplastic diseases, and physio-
logic and pathologic human pregnancy.
IMMUNE RESPONSE IN
HIV INFECTION
Defective antigen- and mitogen-stimulated IL-2
production has been described in HIV infection
since 1985’9. Analyses of IL-2 production showed
that subtle and complex defects in T helper (TH)
function are present in approximately 2/3 of HIV-
seropositive asymptomatic individuals indepen-
dently of a decline in CD4 counts.1 These TH
defects are predictive for: 1) rate of decline in the
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number of CD4+ T lymphocytes;
11 2) time to diag-
nosis of AIDS; lz and 3) time to death.z Therefore,
IL-2 production defects are predictive for three
clinically relevant endpoints in HIV infection. Be-
cause in this infection IL-2 production is impaired
(and IL-2 mainly stimulates CMI) and HI is abnor-
mally activated3 and because different cytokines
stimulated CMI or HI, a number of laboratories
examined type and type 2 cytokine production by
PBMC of HIV-seropositive individuals. The results
showed that, beside IL-2, IL-12 is also severely
defective in HIV infection, whereas the produc-
tion of the type 2 cytokines IL-4, IL-5, IL-6, and
IL-10 is enhanced. 6,7 Because different cytokines
are responsible for diverse biologic effects, the
concentration of IgE (IL-4-driven) and eosinophils
(IL-5-driven) was analized in HIV-seropositive in-
dividuals. As expected, hyperlgE
4 and hypereo-
sinophilia
15 were detected in those patients inwhom
defective (IL-2-, IL-12-, and IFN’y-driven) delayed
type hypersensitivity reactions (DTH) to common
recall antigens is present.
6 Additionally, hyper IgE,
hypereosinophilia, and impaired DTH were recog-
nized as predictors of poor prognosis in HIV-sero-
positive individuals. 14-16 These data led to the for-
mulation of the hypothesis that a type 1-to-type 2
cytokine shift is present in HIV infection. 6’7 Corol-
lary to the hypothesis is the prediction that strong
type cytokine production and well preserved CMI
would correlate with lack of disease progression.
Because HIV infection results in different clini-
cal outcomes,7 markers of progression and protec-
tion were analyzed in HIV-seropositive individuals
progressing toward AIDS and in those patients, de-
fined as long term non-progressors (LTNP), who
do not show signs of disease and maintain stable
CD4 counts, despite a long-lasting HIV infection.
Type and type 2 cytokine production was ex-
amined in pediatric and adult cohorts to analyze
similarities between vertically-transmitted and
adult-acquired HIV infection. In both cohorts data
obtained in LTNP were compared to those of pa-
tients with progressive HIV infection. Both in adult-
acquired and vertically-transmitted infection type
cytokine production was significantly augmented
and type 2 cytokine production was significantly
reduced in HIV-seropositive LTNP individuals
compared to HIV-seropositive individuals with pro-
gressive HIV infection.8a9 Therefore, cytokine pro-
duction profiles by in vitro PHA-stimulated PBMC
can distinguish between HIV-seropositive patients
with different patterns of disease progression in that
a type predominance is evident in LTNP patients
whereas a type 2 predominance is characteristic of
patients with progressive HIV infection. To
summarize, strong CMI appears to be at least par-
tially protective against the progression of HIV in-
fection.
IMMUNE RESPONSE IN
NEOPLASTIC DISEASES
Type cytokines have been shown to have anti-
tumor and anti-metastatic effects in murine tumors.
Thus: 1) IL-2, IL-12 and IFNy activate cytotoxicT
lymphocyte- and natural killers cell (NK)-mediated
cytolytic functions that provide effective anti-tumor
defense mechanisms;z-zz 2) IL-2 induces the trans-
formation ofNK into lymphokine activated killers,
associated with improved capacity to destroy tumor
cells;z3 3) IL-12 has direct anti-tumor activity in
murine tumors,z-zz In contrast, type 2 cytokines,
and IL-10 in particular, were shown to be associated
with enhanced tumor growth, z4z9 Thus, IL-10 pro-
duction was reported to be elevated in certain tu-
mors including bronchogenic carcinoma, renal cell
cancer, basal and squamous cell carcinomas,
lymphomas, gliomas, and melanomas,z4z9 We ana-
lyzed antigen-and mitogen-stimulated IL-2 produc-
tion in newly diagnosed, untreated patients with
Hodgkin’s lymphoma. Additionally, we analyzed
IFNy, IL-2, IL-4, IL-10 production in women with
cervical intraepithelial neoplasia of the portio.
Hodgkin’s Lymphoma
Similarly to the situation observed in HIV infection,
mitogen-stimulated IL-2 production is known to be
defective in patients with Hodgkin’s lymphoma.
IL-2 defects are accompanied by a variety of alter-
ations in CMI including deficient DTH to common
recall antigens, delayed allograft rejection, and al-
terations in graft versus host reactivity in vivo.3-33
We analyzed in details IL-2 defects in newly diag-
nosed, untreated Hodgkin’s disease patients using
the same methods employed in HIV-seropositive
individuals.1 Thus, we assessed in vitro TH func-
tion by measuring IL-2 production in response to
recall antigens, HLA alloantigens, and phytohe-
magglutinin because these different antigens are
known to activate the immune response via diverse
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TH-antigen presenting cell pathways.
34 Similarly to
what was observed in HIV-seropositive patients, we
verified that defective TH function is detected in
the majority of Hodgkin’s lymphoma patients.
35 Ad-
ditionally we observed that the more impaired pro-
files ofTH dysfunction were associated with a more
severe clinical presentation and with less favorable
hematological parameters.
35
Cervical Intraepithelial Neoplasia (CIN)
of the Portio
Genital infection with human papillomavirus
(HPV) is correlated with high risk of malignant
transformation, and HPV-associated cervical intra-
epithelial neoplasia (CIN) of the portio is likely to
be invasive.36-39 We analyzed immune profiles in
women with CIN associated with HPV infection
limited to the portio or involving other ites of the
lower genital tract.We observed that antigen-stimu-
lated IL-2 production was reduced in the patients
with HPV infection extended beyond the portio
compared to the women with HPV infection limited
to the portio.4 Additionally, we observed that mito-
gen-stimulated IL-4 and IL-10 production was ele-
vated in the former compared to the latter group.
4
Thus, a different pattern of cytokine production
was observed in women with HPV infection con-
fined to the portio (high antigen-stimulated IL-2
production; low mitogen-stimulated IL-4 and
IL-10 production) compared to patients with HPV
infection extending beyond the portio (low antigen-
stimulated IL-2 production; high mitogen-stim-
ulated IL-4 and IL-10 production). Briefly, we
verified that a more extended and aggressive HPV
infection is associated with defective type cyto-
kine production and augmented type 2 cytokine
production. Thus, production of cytokines that
mainly enhance potentially protective cell-medi-
ated immunity is impaired in women in whom ex-
tended HPV infection is observed.4
IMMUNE RESPONSE IN HUMAN
PHYSIOLOGIC AND
PATHOLOGIC PREGNANCY
Finally, because: 1) the fetus expresses human leu-
kocyte antigens (HLA) of both maternal and pater-
nal origin, and is thus partly allogeneic to the
mother;41 2) despite being biological allografts, fe-
tuses are not normally rejected by the maternal
immune system; and 3) allograft rejection is classi-
cally a type 1 cytokine-dependent CMI-mediated
phenomenon,4z we analyzed type and type 2 cyto-
kines in human pregnancies. Support to the hypoth-
esis that a type 1-to type 2 shift is observed in
pregnancy stems from the observations that: 1)
pregnancy in mice is a TH2-related phenomenon
as a shift from predominant THl-driven CMI to
predominant TH2-driven HI is present;
43 and 2)
pregnant women exhibit clinical remission ofCMI-
mediated autoimmune diseases such as rheumatoid
arthritis as well as exacerbation of autoantibody-
mediated autoimmune pathologies such as systemic
lupus erythematosus, myasthenia gravis, and
Graves’ disease.44-47 Support for the hypothesis that
this shift could be associated with successful preg-
nancy derives from the following observations: 1)
high concentrations of type 1 cytokines are associ-
ated with spontaneous abortions and fetal reabsorp-
tion in mice;
43 and 2) recurrent spontaneous abortion
in humans is correlated with TH1 type immunity
to the trophoblast.48’49
Again, we analyzed antigen-and mitogen-stimu-
lated cytokine production in pregnant women un-
dergoing physiologic pregnancy at the time the
blood was drawn. Spontaneous abortions were ob-
served in a percentage ofwomen during follow-up,
whereas a number of women delivered babies that
were small for gestational age (SGA). To summarize
the data, we observed that: 1) an increase in the
production of type 2 cytokines by in vitro mitogen-
stimulated PBMC was accompanied by a parallel
decrease in the production of type cytokines in
successful human pregnancy, with a type 1-to-type
2 shift observed in the third trimester;s and 2) the
absence of a type 2 bias was associated with, and
possibly a predictor of, pathologic events such as
spontaneous abortions and the birth of SGA ba-
bies.5 Thus, cytokine modulation may be associ-
ated with successful human pregnancy.
CONCLUSIONS
In this brief review we have summarized data ob-
tained in a number ofhuman pathologic and physio-
logic conditions. The results underline the impor-
tance of fighting the battle with the right weapon
and suggest that choosing the wrong defense mech-
anism could have deleterious effects. Pharmaco-
logic immune modulation has still not been finely
tuned since most drugs induce immunosuppression
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rather than redirection of the immune response. A
primary challenge for the future will be to learn how
to teach the immune system to react to antigenic
stimulation, picking the most advantageous way for
the host.
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